ZR2 follow-up immunotherapy for newly diagnosed mantle cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (ZR2 followed by chemoinmunotherapy) for people newly diagnosed with mantle cell lymphoma. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have mantle cell lymphoma that has not been treated before.
- You need to have at least one tumor that can be seen on a scan (like a PET/CT).
- Your organs (like bone marrow, liver, kidneys, and heart) must be working well enough.
- You cannot have a history of HIV, active hepatitis B or C, or other serious illnesses.
- You must agree to use effective birth control if you are male, for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP or R-DHAP) helps people with untreated mantle cell lymphoma. It is for adults up to age 70 who are healthy enough for intensive treatment.
Hear when a new Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.